Avista's mission is to develop innovative gene therapies for retinal diseases, including rare, inherited conditions that have a profound impact on patients' quality of life.

We leverage our computationally guided scAAVengr platform to generate and validate a toolkit of proprietary AAV vectors that overcome the most significant obstacles to effective gene therapies, including cell-type specific delivery, reduced dosages, and efficient expression, using a minimally invasive intravitreal approach.

Our quantitative, in vivo-based approach and clinical ophthalmology expertise allow us to rapidly translate new gene therapies to the clinic.

Avista is a UPMC Enterprises portfolio company founded based on the research of Drs. Leah Byrne, Jose Sahel, and Paul Sieving.

Avista Therapeutics

The Pittsburgh office focuses on advanced research and development in gene therapy and bioinformatics, supporting biopharmaceutical innovation.

Pittsburgh

Rob Lin, PhD, CFA

Jane Opgaard

This department conducts scientific research and develops innovative solutions and products.

Research and Development

This department focuses on the application of computational and statistical methods to analyze biological data.

Bioinformatics Research

This department focuses on developing and applying advanced algorithms and statistical models to enable machines to learn from and make predictions based on data.

Avista Therapeutics

Org chart

Teams

Research and Development

Bioinformatics Research

Machine Learning

Offices

Avista Therapeutics

Org chart

Teams

Research and Development

Bioinformatics Research

Machine Learning

Offices

Related companies